首页 › 基金 › Bain Capital Life Sciences Investors, LLC › CCCC
Bain Capital Life Sciences Investors, LLC 对 CCCC 的持仓历史
C4 THERAPEUTICS INC · 医疗保健
Bain Capital Life Sciences Investors, LLC 在 Q3 2026 的 13F 申报中披露持有 CCCC(C4 THERAPEUTICS INC)7,171,910 股,市值约 US$23.9M,约占其申报组合的 1.64%,在其申报持仓中市值排名第 14 位。 Bain Capital Life Sciences Investors, LLC 最近 13 个申报季度中有 13 个季度披露了 CCCC 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Bain Capital Life Sciences Investors, LLC 对 CCCC 的持仓演变
Bain Capital Life Sciences Investors, LLC 于 Q3 2023 首次披露 CCCC 持仓:1,642,210 股(约 US$3.1M)。 该持仓在 Q2 2026 达到峰值 7,171,910 股,市值约 US$33.5M。 在 13 次申报中,Bain Capital Life Sciences Investors, LLC 1 次增持、2 次减持、9 次保持不变。 最近一期申报(Q3 2026)显示持股 7,171,910 股、市值约 US$23.9M。 持仓曾出现大幅变动:Q1 2024 减持约 30% (随后一个季度股价下跌 43%)、Q4 2025 增持约 545% (随后一个季度股价上涨 38%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 1.64M | $3.05M | 新进 |
| Q4 2023 | 1.64M | $9.28M | 持有 |
| Q1 2024 | 1.14M | $9.33M | 减持 |
| Q2 2024 | 1.11M | $5.14M | 减持 |
| Q3 2024 | 1.11M | $6.34M | 持有 |
| Q4 2024 | 1.11M | $4.00M | 持有 |
| Q1 2025 | 1.11M | $1.78M | 持有 |
| Q2 2025 | 1.11M | $1.59M | 持有 |
| Q3 2025 | 1.11M | $2.47M | 持有 |
| Q4 2025 | 7.17M | $13.70M | 增持 |
| Q1 2026 | 7.17M | $18.86M | 持有 |
| Q2 2026 | 7.17M | $33.49M | 持有 |
| Q3 2026 | 7.17M | $23.88M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CCCC 与 13F 数据
CCCC(C4 THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 46 只申报持有 CCCC,申报仓位最大的包括:RA CAPITAL MANAGEMENT, L.P. (US$37.4M), Lynx1 Capital Management LP (US$34.2M), Soleus Capital Management, L.P. (US$15.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CCCC 的基金
- RA CAPITAL MANAGEMENT, L.P. 8.00M 股 · $37.36M · Q2 2026
- Lynx1 Capital Management LP 7.33M 股 · $34.22M · Q2 2026
- Soleus Capital Management, L.P. 3.38M 股 · $15.78M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 3.45M 股 · $11.50M · Q3 2026
- Ikarian Capital, LLC 2.43M 股 · $11.36M · Q2 2026
- STEMPOINT CAPITAL LP 3.29M 股 · $10.97M · Q3 2026
- HighVista Strategies LLC 873.28K 股 · $2.91M · Q3 2026
- PLATINUM INVESTMENT MANAGEMENT LTD 577.53K 股 · $1.92M · Q3 2026
- Squadron Capital Management LLC 400.00K 股 · $1.87M · Q2 2026
- Seven Fleet Capital Management LP 381.17K 股 · $1.78M · Q2 2026
更多关于 Bain Capital Life Sciences Investors, LLC
常见问题
How long has Bain Capital Life Sciences Investors, LLC held CCCC?
Bain Capital Life Sciences Investors, LLC has disclosed CCCC holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bain Capital Life Sciences Investors, LLC's current position in CCCC?
As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 7.17M shares of CCCC (C4 THERAPEUTICS INC), valued at $23.88M, representing 1.64% of its reported portfolio and ranking #14.
Has Bain Capital Life Sciences Investors, LLC been buying or selling CCCC?
In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in CCCC. The position peaked in Q2 2026 at 7.17M shares.
Which other funds hold CCCC?
Other major institutional holders of CCCC include RA CAPITAL MANAGEMENT, L.P., Lynx1 Capital Management LP, Soleus Capital Management, L.P., among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.